Bioniche secures $19m finance facility
Monday, 19 March, 2012
Bioniche Life Sciences (ASX:BNC) has accepted a US$20 million ($18.9 million) financing offer from US financing company Capital Royalty.
Investment funds managed by Capital Royalty have agreed to grant Bioniche a five-year loan with a partially-deferred interest rate of 15%.
Bioniche, a Canadian dual-listed technology company, has also agreed to pay an additional royalty interest of 2% of all product sales revenues during the term of the loan.
Announcing the deal, Bioniche CEO Graeme McRae said he was pleased to “be able to receive such an investment with no dilution of our equity shareholders.”
Bioniche has around 200 employees. The company listed on the ASX in January last year, following a $12.47 million CDI placement. It has been listed on the Toronto stock exchange since 1992.
The company's Australian division concentrates on the animal health segment, but the company also has human health and food safety operating units.
In February, Bioniche reported a C$4 million ($4.04 million) net loss for the second quarter, up 72% from a year earlier. At the time, the company revealed it was seeking non-dilutive financing to address a cash shortfall.
Capital Royalty concentrates on the healthcare sector, making intellectual property investments through its managed investment funds.
Bioniche (ASX:BNC) shares were trading unchanged for the day at $0.620 by 4pm on Monday. The price is down from $1.500 at time of listing.
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
